ライフサイエンスコーパス: pamidronate

1 been shown to be as effective as intravenous pamidronate.

2 renal function before the administration of pamidronate.

3 site in men treated with both leuprolide and pamidronate.

4 ng thalidomide (THAL, 200 mg/d) with monthly pamidronate.

5 in cultures treated with the bisphosphonate pamidronate.

6 also increased in osteoblasts cultured with pamidronate.

7 controlled, randomized, nonblinded trial of pamidronate (30 mg intravenously every 3 mo) with vitami

8 ve either leuprolide alone or leuprolide and pamidronate (60 mg intravenously every 12 weeks).

9 ults of two randomized trials that evaluated pamidronate 90 mg administered intravenously every month

10 Intravenous (IV) pamidronate 90 mg delivered over 1 to 2 hours every 3 to

11 ession fracture from osteopenia, intravenous pamidronate 90 mg delivered over at least 2 hours or zol

12 mg subcutaneously every 4 weeks, intravenous pamidronate 90 mg over no less than 2 hours, or zoledron

13 one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion

14 tic bone lesion were given either placebo or pamidronate (90 mg) as a two-hour intravenous infusion m

15 sumab, 120 mg subcutaneously, every 4 weeks; pamidronate, 90 mg intravenously, every 3 to 4 weeks; or

16 is directly, we injected postnatal rats with pamidronate, a bisphosphonate that reduces bone resorpti

17 of infected, reconstituted hu-SCID mice with pamidronate, a human V gamma 2V delta 2 T cell-specific

18 dy that treatment of murine macrophages with pamidronate, a second generation aminobisphosphonate, in

19 Pamidronate, a second-generation bisphosponate, has been

20 2H NMR measurements of side-chain 2H-labeled pamidronate, alendronate, zoledronate, and risedronate o

21 Pamidronate, an aminobisphosphonate, has been shown to l

22 icacy could be evaluated in 198 who received pamidronate and 179 who received placebo.

23 tment could be evaluated in 196 who received pamidronate and 181 who received placebo.

24 One hundred eighty-two patients who received pamidronate and 189 who received placebo were assessable

25 80 of 382 randomized patients, 185 receiving pamidronate and 195 receiving placebo.

26 Other bisphosphonates, including pamidronate and clodronate, seem to be ineffective in th

27 oxyalkyl, and sulfanylalkyl) derivatives of pamidronate and one alendronate, a molecular field analy

28 Pamidronate and other bisphosponates, used as supportive

29 ustained significant differences between the pamidronate and placebo groups in self-reported pain mea

30 nly used in bone resorption therapy, such as pamidronate and risedronate.

31 nitrogen-containing bisphosphonates, such as pamidronate and risedronate.

32 after lung transplant and improved with both pamidronate and time.

33 ng free divalent ion concentrations, whereas pamidronate and zoledronate appear to act on the hFOB ce

34 Pamidronate and zoledronate decreased hFOB cell prolifer

35 Both pamidronate and zoledronate increase hFOB cell bone form

36 Intravenous use of pamidronate and zoledronic acid is associated with most

37 ed treatment with the potent bisphosphonates pamidronate and zoledronic acid seems to be well tolerat

38 The choice between pamidronate and zoledronic acid will depend on choosing

39 t supports that oral clodronate, intravenous pamidronate, and intravenous zoledronic acid are superio

40 decreased with monthly infusions of 90 mg of pamidronate, and this effect was maintained for at least

41 t and prostate cancer patients (ibandronate, pamidronate, and zoledronic acid).

42 sphosphonates, particularly the potent agent pamidronate (Aredia), will relieve metastatic bone pain

43 t, the only agent common to all patients was pamidronate (Aredia).

44 Treatment with 90 mg of pamidronate as a 2-hour intravenous infusion every 4 wee

45 Monthly infusions of pamidronate as a supplement to chemotherapy can protect

46 Long-term monthly infusions of pamidronate as an adjunct to chemotherapy are superior t

47 Pamidronate at an intraperitoneal dose of 10 mg/kg/day f

48 Patients began therapy with pamidronate at or below the recommended dose of 90 mg, i

49 Pamidronate-augmented TNF-alpha production by macrophage

50 ore, pretreatment of murine macrophages with pamidronate before stimulation with IFN-gamma significan

51 all-cell lung, 183; other, 168) and 362 with pamidronate (breast, 254; myeloma, 108).

52 The bisphosphonate pamidronate decreases skeletal complications and improve

53 Intravenous pamidronate disodium (90 mg) or placebo was administered

54 Pamidronate disodium failed to demonstrate a significant

55 Bisphosphonates such as pamidronate disodium inhibit osteoclast-induced bone res

56 the effect of an intravenous bisphosphonate, pamidronate disodium, on pain control in metastatic pros

57 s were treated with docetaxel, docetaxel and pamidronate disodium, or docetaxel and cyclophosphamide.

58 ard dosing regimen of zoledronic acid and/or pamidronate disodium.

59 Pamidronate does increase the size of the osteoclasts, i

60 However, pamidronate does not increase survival and is associated

61 Pamidronate does not inhibit the gene expression of the

62 hat clinicians consider reducing the initial pamidronate dose in patients with pre-existing renal imp

63 ed 9 or more doses of zoledronic acid and/or pamidronate during the first 10 to 15 months of therapy.

64 ned the effects of alendronate, risedronate, pamidronate, etidronate, and clodronate on apoptosis and

65 dronate (n = 34) or pamidronate (n = 17) and pamidronate followed by zoledronate (n = 33).

66 Patients received pamidronate for 15 to 48 mo before presentation with ren

67 The patients treated with pamidronate gained 8.8 +/- 2.5% and 8.2 +/- 3.8% in spin

68 eletal events was significantly lower in the pamidronate group (24 percent) than in the placebo group

69 had any skeletal complication was 56% in the pamidronate group and 67% in the placebo group (P = .027

70 ne resorption markers were suppressed in the pamidronate group compared with placebo.

71 rst skeletal complication was greater in the pamidronate group than in the placebo group (13.1 vs. 7.

72 ation of performance status (P=0.027) in the pamidronate group than in the placebo group.

73 of skeletal events per year was less in the pamidronate-group (1.3) than in placebo-treated patients

74 eveloped any skeletal event was lower in the pamidronate-group (P = .015).

75 nd six fractures occurred in the control and pamidronate groups, respectively (p > 0.2).

76 The patients who received pamidronate had significant decreases in bone pain and n

77 synthase inhibitors, such as risedronate or pamidronate, had little or no activity.

78 ogen-containing bisphosphonates alendronate, pamidronate, homorisedronate, and risedronate but was le

79 nsplantation, all patients received 90 mg of pamidronate i.v. every 12 weeks, regardless of pretransp

80 fety of continued treatment with intravenous pamidronate infusions for up to 2 years.

81 Bisphosphonates such as pamidronate inhibit osteoclastic activity and reduce bon

82 trial was conducted using the bisphosphonate pamidronate intravenously in patients with new renal tra

83 Pamidronate is a useful adjunct to standard chemotherapy

84 riments indicate that the NH3(+)-terminus of pamidronate is close to the bone mineral surface, and a

85 Pamidronate is effective in reducing bony complications

86 IV pamidronate is recommended in women with pain caused by

87 Binding of pamidronate is well described by a Langmuir-like isother

88 Pamidronate is, therefore, a new lead compound for the s

89 nts overall, stratum 2 patients who received pamidronate lived longer than those who received placebo

90 studies suggest that bisphosphonates such as pamidronate may be efficacious.

91 This pamidronate-mediated augmentation of TNF-alpha productio

92 e an approximately 30-38 A2 surface area per pamidronate molecule and a deltaG = -4.3 kcal mol(-1).

93 ate therapy included zoledronate (n = 34) or pamidronate (n = 17) and pamidronate followed by zoledro

94 Etidronate, alendronate, pamidronate, olpadronate, or amino-olpadronate (IG9402,

95 TEDOR of [13C3, 15N] pamidronate on bone shows that the bisphosphonate binds

96 onate, were also compared with the action of pamidronate on proliferation of immortalized human fetal

97 hylamino)ethyl diphosphate, alendronate, and pamidronate on the pools of metabolites related to monot

98 therapy were randomized to receive 90 mg of pamidronate or placebo as a 2-hour intravenous infusion

99 randomly assigned to receive either 90 mg of pamidronate or placebo intravenously every 3 to 4 weeks

100 vations strongly suggest that treatment with pamidronate or zoledronate enhances the differentiation

101 reatment of PC3, DU145, and LNCaP cells with pamidronate or zoledronate significantly reduced the gro

102 studied 22 patients who received intravenous pamidronate or zoledronic acid for a duration of 3.6 yea

103 wever, the panel recommends only intravenous pamidronate or zoledronic acid in light of the use of th

104 Patients who received bisphosphonates (pamidronate or zoledronic acid) were identified.

105 no direct comparisons between clodronate and pamidronate or zoledronic acid, the superiority of one a

106 24 cycles in patients treated with 90 mg of pamidronate (P = .028, .023, and .008, respectively).

107 orubicin (Doxo) and coated with bone-seeking pamidronate (Pam) for the targeted treatment of malignan

108 Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal

109 ral mucosal tissue, we studied the effect of pamidronate (PAM), one of the BPs most commonly administ

110 In the pamidronate (Pam)-treated mice, but not control non-drug

111 Pamidronate preserved vertebral BMD during treatment and

112 Pamidronate prevents bone loss in the hip and lumbar spi

113 Monthly infusions of pamidronate provide significant protection against skele

114 Treatment with the bisphosphonate pamidronate reduces skeletal complications and may also

115 The cost of pamidronate reflected the average wholesale price of the

116 n vivo (potency: risedronate > alendronate > pamidronate) requires expression of the Vgamma2Vdelta2 T

117 mplication was longer for patients receiving pamidronate than for those given placebo (P = .049).

118 complication was significantly less for the pamidronate than the placebo group at 15, 18, 21, and 24

119 alcemia were also statistically less for the pamidronate than the placebo group.

120 In pamidronate, the motion is well simulated by a gauche+/g

121 similar dosing guidelines are available for pamidronate, the Update Committee recommends that clinic

122 The temporal association between pamidronate therapy and the development of renal insuffi

123 The cost of pamidronate therapy exceeded the cost savings from preve

124 hough survival was not different between the pamidronate-treated group and placebo patients overall,

125 skeletal complication was 13.9 months in the pamidronate-treated women and 7.0 months in the placebo

126 Using flow cytometry, pamidronate treatment (100 microM) was shown to induce s

127 In addition, pamidronate treatment increased total cellular protein,

128 We also show that pamidronate treatment increases TNF-alpha production in

129 Pamidronate treatment was associated with development of

130 6 to 12, the subjects were observed without pamidronate treatment.

131 e effects in vivo of the bisphosphonate drug pamidronate, used in bone resorption therapy, were inves

132 -hoc evaluation of the cost-effectiveness of pamidronate using the results of two randomized trials t

133 We conclude that pamidronate was more effective than control in improving

134 on in mice (giving a 60% survival rate), but pamidronate was not effective.

135 Pamidronate was safe and well tolerated during the 21 cy

136 Pamidronate was tolerated well.

137 Pamidronate was well tolerated.

138 Pamidronate was well tolerated.

139 rseded by second-generation bisphosphonates (pamidronate), which are more potent and do not have adve

140 Pamidronate, which is a member of the class of bisphosph

141 Treatment subjects (PAM) received pamidronate with vitamin D and calcium at baseline and a

142 15 minutes), versus the less expensive drug, pamidronate, with its longer infusion time (2 hours).

143 dental extraction (P = .009), treatment with pamidronate/zoledronate (P = .009), longer follow-up tim